Balyasny Asset Management L.P. Acquires 66,993 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Balyasny Asset Management L.P. lifted its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,187,102 shares of the biotechnology company's stock after purchasing an additional 66,993 shares during the quarter. Balyasny Asset Management L.P. owned 2.40% of REGENXBIO worth $9,176,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of REGENXBIO by 67.0% during the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of REGENXBIO by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company's stock valued at $9,054,000 after purchasing an additional 21,234 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company's stock worth $8,460,000 after buying an additional 5,574 shares during the last quarter. Assenagon Asset Management S.A. grew its position in REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company's stock valued at $6,621,000 after buying an additional 296,700 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in REGENXBIO during the fourth quarter worth about $3,865,000. 88.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. HC Wainwright reduced their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, March 17th. Morgan Stanley upped their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Royal Bank of Canada restated an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Finally, Leerink Partners set a $24.00 target price on shares of REGENXBIO in a report on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Trading Up 6.0%

Shares of NASDAQ RGNX traded up $0.45 during midday trading on Monday, hitting $7.97. 1,117,594 shares of the company's stock were exchanged, compared to its average volume of 850,257. The business's fifty day moving average price is $7.36 and its two-hundred day moving average price is $7.99. The company has a market cap of $399.43 million, a price-to-earnings ratio of -1.58 and a beta of 1.11. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $16.85.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.35 by ($0.23). REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Equities analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.